We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+14.5%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
+$94.6M
(+39%)
Cap. Flow
+$76.8M
Cap. Flow
% of AUM
22.61%
Top 10 Holdings %
Top 10 Hldgs %
47.34%
Holding
100
New
32
Increased
8
Reduced
12
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$16.1M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$12.2M |
| 3 |
Corbus Pharmaceuticals
CRBP
|
+$9.98M |
| 4 |
Glaukos
GKOS
|
+$9.58M |
| 5 |
Arrowhead Research
ARWR
|
+$8.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALIM
Alimera Sciences
ALIM
|
+$12M |
| 2 |
argenx
ARGX
|
+$9.89M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$6.82M |
| 4 |
Insmed
INSM
|
+$4.43M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$3.51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.3% |
| 2 | Consumer Discretionary | 1.17% |
| 3 | Consumer Staples | 0.08% |
| 4 | Industrials | 0.03% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vera Therapeutics
VERA
$2.32B
| $30.2M | 8.9% |
684,000
-30,000
| -4% | -$1.14M |
|
2
ADMA Biologics
ADMA
$2.01B
| $27.2M | 8% |
1,360,000
-150,000
| -10% | -$2.33M |
|
|
3
Sarepta Therapeutics
SRPT
$1.62B
| $21.2M | 6.25% |
170,000
+88,100
| +108% | +$12.2M |
|
|
4
Edwards Lifesciences
EW
$49.2B
| $14.6M | 4.31% |
+222,000
| New | +$16.1M |
|
5
Xenon Pharmaceuticals
XENE
$6.23B
| $14.2M | 4.18% |
360,600
| – | – |
|
6
Zevra Therapeutics
ZVRA
$558M
| $11.8M | 3.47% |
1,700,000
+537,584
| +46% | +$3.65M |
|
|
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $11.3M | 3.32% |
154,000
-39,000
| -20% | -$2.93M |
|
|
SLNO
8
DELISTED
Soleno Therapeutics
SLNO
| $10.7M | 3.16% |
212,909
| – | – |
|
|
9
Glaukos
GKOS
$9.18B
| $10M | 2.95% |
+77,000
| New | +$9.58M |
|
|
10
Insmed
INSM
$22.7B
| $9.49M | 2.79% |
130,000
-60,000
| -32% | -$4.43M |
|
11
Merit Medical Systems
MMSI
$4.71B
| $8.4M | 2.47% |
+85,000
| New | +$7.78M |
|
12
Rezolute
RZLT
$461M
| $8.24M | 2.43% |
1,700,000
| – | – |
|
13
Vaxcyte
PCVX
$7.7B
| $8.23M | 2.42% |
+72,000
| New | +$6.49M |
|
|
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
| $8M | 2.36% |
610,000
| – | – |
|
15
Viking Therapeutics
VKTX
$3.89B
| $7.98M | 2.35% |
126,000
+4,000
| +3% | +$235K |
|
|
CPRX
16
DELISTED
Catalyst Pharmaceutical
CPRX
| $7.65M | 2.25% |
385,000
-115,000
| -23% | -$2.13M |
|
|
CTNM
17
Contineum Therapeutics
CTNM
$526M
| $7.07M | 2.08% |
369,126
-60,214
| -14% | -$1.15M |
|
|
18
Arrowhead Research
ARWR
$12.1B
| $6.88M | 2.02% |
+355,000
| New | +$8.66M |
|
19
Savara
SVRA
$1.08B
| $6.68M | 1.97% |
1,575,000
| – | – |
|
20
iRhythm Holdings
IRTC
$3.94B
| $6.38M | 1.88% |
+86,000
| New | +$6.85M |
|
21
Evolus
EOLS
$398M
| $5.75M | 1.69% |
+355,000
| New | +$4.96M |
|
22
Establishment Labs
ESTA
$2.66B
| $5.67M | 1.67% |
+131,000
| New | +$5.7M |
|
23
RxSight
RXST
$253M
| $5.54M | 1.63% |
+112,000
| New | +$5.74M |
|
24
Axsome Therapeutics
AXSM
$11.8B
| $5.21M | 1.53% |
58,000
+8,000
| +16% | +$698K |
|
25
Skye Bioscience
SKYE
$21.2M
| $5.14M | 1.51% |
1,315,146
-34,947
| -3% | -$196K |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, Altium Capital Management held 100 positions worth $340M, up 39% from $245M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Altium Capital Management deployed $76.8M of net new capital in Q3 2024, opening 32 new positions and adding to 8 existing holdings. Its largest new stake was Edwards Lifesciences: 222,000 shares worth $14.6M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Insmed, an estimated $4.43M trimmed.
- Altium Capital Management's largest Q3 2024 buy was Edwards Lifesciences: 222,000 shares worth $14.6M.
- Altium Capital Management added most to Sarepta Therapeutics in Q3 2024, an estimated $12.2M increase.
- Altium Capital Management's biggest Q3 2024 reduction was Insmed, cutting an estimated $4.43M.
- Altium Capital Management fully exited Alimera Sciences in Q3 2024, selling an estimated $12M.
- Altium Capital Management's ten largest holdings make up 47% of its $340M portfolio in Q3 2024.
- Altium Capital Management opened 32 new positions and closed 21 in Q3 2024.
- Altium Capital Management's portfolio value rose 39% quarter-over-quarter to $340M.
Based on Altium Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.